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Abstract
A number of solid tumors, such as alveolar
rhabdomyosarcoma, synovial sarcoma, and myxoid
liposarcoma, are associated with recurrent
translocation events that encode fusion proteins.
Ewing’s sarcoma is a pediatric tumor that serves as a
prototype for this tumor class. Ewing’s sarcomas
usually harbor the (11;22)(q24;q12) translocation.
The t(11;22) encodes the EWS/FLI fusion oncoprotein.
EWS/FLI functions as an aberrant transcription
factor, but the key target genes that are involved in
oncogenesis are largely unknown. Although some
target genes have been defined, many of these have
been identified in heterologous model systems
with uncertain relevance to the human disease.
To understand the function of EWS/FLI and its targets
in a more clinically relevant system, we used
retroviral-mediated RNAi to ‘‘knock-down’’ the fusion
protein in patient-derived Ewing’s sarcoma cell lines.
By combining transcriptional profiling data from three
of these lines, we identified a conserved transcriptional
response to EWS/FLI. The gene that was most
reproducibly up-regulated by EWS/FLI was NR0B1.
NR0B1 is a developmentally important orphan
nuclear receptor with no previously defined role in
oncogenesis. We validated NR0B1 as an EWS/
FLI-dysregulated gene and confirmed its expression in
primary human tumor samples. Functional studies
revealed that ongoing NR0B1 expression is required
for the transformed phenotype of Ewing’s sarcoma.
These studies define a new role for NR0B1 in
oncogenic transformation and emphasize the utility
of analyzing the function of EWS/FLI in Ewing’s
sarcoma cells. (Mol Cancer Res 2006;4(11):851–9)
Introduction
The ETS family of transcription factors is important for the
development of a wide variety of malignancies (1). With the
recent finding of translocations involving two different ETS
family members in prostate cancer, alterations of ETS proteins
may be the most common abnormality in human cancer (2).
Understanding the mechanisms by which this transcription
factor family contributes to oncogenesis may lead to new
diagnostic, prognostic, and therapeutic approaches.
Ewing’s sarcoma is a highly malignant bone-associated
pediatric cancer that serves as an excellent model to understand
the role of ETS family members in tumor formation. Most cases
of Ewing’s sarcoma harbor a recurrent translocation,
(11;22)(q24;q12), that encodes the EWS/FLI fusion oncopro-
tein (3). EWS is a protein of uncertain function, whereas FLI
is an ETS family member (3). EWS/FLI is an aberrant
transcription factor that requires both the FLI-derived ETS
DNA binding domain, and the EWS-derived strong transcrip-
tional activation domain for its oncogenic activity (4-6). The
target genes that mediate EWS/FLI function are only beginning
to be understood.
The cell of origin of Ewing’s sarcoma is unknown, hence,
most studies of EWS/FLI have relied on various heterologous
cell types with uncertain relevance to the human disease (e.g.,
refs. 5, 7-10). In addition, it has been difficult to functionally
validate putative EWS/FLI targets as being important for the
oncogenic phenotype of Ewing’s sarcoma because of the lack of
a clinically relevant model system to study these proteins. Thus,
it is uncertain whether many of the previously identified EWS/
FLI targets are involved in the bona fide tumor.
We recently developed an approach to study the function of
EWS/FLI in its native cellular context (11). We used retroviral-
mediated RNAi to knock-down endogenous EWS/FLI expres-
sion in patient-derived Ewing’s sarcoma cells. When coupled
with microarray analysis, we were able to define the transcrip-
tional response to EWS/FLI in Ewing’s sarcoma. Although this
was an important next step, one drawback of our earlier work
is that it was limited to a single Ewing’s sarcoma cell line,
A673. Thus, some of the EWS/FLI-regulated genes which we
identified are likely to be specific to A673, and not generally
applicable.
We now report an analysis of EWS/FLI-regulated genes
across three Ewing’s sarcoma cell lines. In this way, we have
defined a ‘‘core’’ transcriptional response to the fusion protein.
Because these genes are dysregulated in all our analyzed cell
lines, they are likely to be enriched in targets that are required
for tumor formation. Consonant with this expectation, we
identified NR0B1 as an EWS/FLI-regulated gene that is
required for Ewing’s sarcoma oncogenic transformation.
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Mol Cancer Res 2006;4(11). November 2006 851NR0B1 is an orphan nuclear receptor that is important for
adrenal gland development (12). NR0B1 has not been
previously shown to be functionally important for cancer
formation. Our results thus define a functionally important
target gene for EWS/FLI, show a new function for NR0B1, and
provide a link between EWS/FLI and dysregulation of
developmental pathways in pediatric cancer.
Results and Discussion
We analyzed the EWS/FLI-mediated transcriptional profile
in two Ewing’s sarcoma cell lines that had not been previously
evaluated: TC71 and EWS502. Each cell line was infected with
a retrovirus expressing a short hairpin RNA that targeted the
3¶-untranslated region of EWS/FLI (called EF-2-RNAi), or a
negative control retrovirus directed against luciferase (which is
not expressed in these cells; called luc-RNAi). Polyclonal pools
of infected cells were recovered following puromycin selection
and were used for subsequent assays. EWS/FLI was efficiently
knocked-down in each cell line (Fig. 1A). Knock-down of the
fusion protein resulted in a significant reduction of tissue
culture growth (as measured by 3T5 assay; Fig. 1B). The initial
decrease in cell number observed with each retroviral construct
was likely due to incomplete drug selection at the start of the
growth assays, and not increased cell death due to the RNAi
constructs.
4
In addition to growth arrest, TC71 and EWS502 cells with
EWS/FLI knock-down via the EF-2-RNAi construct also
exhibited a significant loss of soft agar colony growth (one
measure of oncogenic transformation; Fig. 1C). Overall, results
from TC71 and EWS502 Ewing’s sarcoma cells contrast with
those we observed for A673 cells harboring the EF-2-RNAi
construct. In the latter case, cells grow normally in tissue
culture, but had lost their oncogenic phenotype, as measured by
soft agar and xenograft assays (11). The differences in growth
observed for all three cell lines suggests that EWS/FLI
contributes different (although not mutually exclusive) func-
tions required for transformation. In the case of TC71 and
EWS502, EWS/FLI contributes a proliferative function
(Fig. 1B). In A673 cells, EWS/FLI is not required for normal
growth in tissue culture, but instead contributes a more limited
oncogenic function (11). The molecular mechanisms that
underlie these differences are currently unknown.
FIGURE 1. EWS/FLI is re-
quired for normal growth and
transformation in TC71 and
EWS502 Ewing’s sarcoma
cells. A. Western blot analysis
reveals decreased levels of
EWS/FLI protein in both
TC71 and EWS502 cell lines
infected with the EF-2-RNAi
retroviral construct, as com-
pared with luc-RNAi control–
infected cells. Tubulin is
shown as a loading control.
B. 3T5 growth assays reveal
that knock-down of EWS/FLI
with the EF-2-RNAi retroviral
construct results in diminished
growth in both TC71 and
EWS502 cell lines, as com-
pared with luc-RNAi control–
infected cells. C. Soft agar
assays show significantly de-
creased colony formation, and
thus,oncogenictransformation
in TC71 and EWS502 cell lines
infected with EF-2-RNAi retro-
viral construct, as compared
with luc-RNAi control–infected
cells. Columns, mean of dupli-
catesamples;bars,SD.
4 M. Kinsey, unpublished observations.
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852To define the common transcriptional profile mediated by
EWS/FLI in these Ewing’s sarcoma cells, we prepared RNA
from EWS502 and TC71 cells harboring each of the RNAi
constructs, and hybridized them to oligonucleotide microarrays.
The complete data set can be found as Supplementary Data 1
online. To minimize the contribution of ‘‘off-target’’ or other
nonspecific effects (13), we identified a second construct
(designated EF-4-RNAi) that also efficiently knocked-down
EWS/FLI expression (data not shown). We prepared cells
containing this additional construct and also used them for
microarray analysis. After preprocessing the data, genes were
sorted based on a two-class distinction (EWS/FLI knock-down
versus control RNAi) using the signal-to-noise metric (Fig. 2A).
Permutation testing (14) revealed that there were 2,046 genes
dysregulated by EWS/FLI at the P < 0.05 significance level:
1,610 were up-regulated and 436 were down-regulated by the
fusion protein. The preprocessed data, the rank-ordered data,
and the lists of up-regulated and down-regulated genes can be
found as Supplementary Data 2 online. These results are
somewhat different from those obtained using A673 cells, in
which there were three to four times as many genes down-
regulated by the fusion than were up-regulated (11). The reason
for this difference is unknown, but emphasizes the importance
of analyzing the EWS/FLI-mediated transcriptional profile in
more than one cell line.
To determine how the data obtained in TC71 and EWS502
cells compared with that obtained in A673 cells, we did a series
of statistical analyses. The two data sets were generated using
different Affymetrix microarray platforms. To allow for gene-
to-gene comparisons, we first mapped all probe sets on both
arrays to their UniGene identifiers. Each data set was limited to
only those genes present on both platforms. We then used Gene
Set Enrichment Analysis (GSEA; ref. 15) for the comparison.
Simply stated, GSEA determines whether one list of genes is
enriched near the top of a second, rank ordered, gene list (15).
When two data sets are well-correlated, one expects such an
enrichment. This enrichment is quantified using a normalized
running-sum statistic called the normalized enrichment score, or
NES, and the maximal and minimal NES (MaxNES and
MinNES, respectively) are reported. In our implementation of
GSEA, the best possible MaxNES is 100 (indicating perfect
correlation), and the worst possible MinNES is 100
(indicating perfect anticorrelation). An empirical P value is
determined by shuffling the rank ordered list, and determining
the number of times that a MaxNES is obtained that is the same,
or greater than, the experimental MaxNES. For inverse
correlations, the same procedure was used, except that the
number of times that a MinNES is obtained that is equal to, or
less than, the experimental MinNES is determined. For
additional details of the procedure as applied in this report,
please refer to the Supplementary Methods online.
We found a highly significant correlation between genes that
were up-regulated by EWS/FLI in both data sets (MaxNES =
34.1; P < 0.0001; Fig. 2B; Table 1). There was also a highly
significant correlation between genes that were down-regulated
by the fusion protein in both data sets (MinNES = 39.6;
P < 0.0001; Fig. 2C; Table 2). Similar correlations were found
when m
2 analysis was used instead (Fig. 2B and C; Tables 1 and
2). Despite the difference in growth response to EWS/FLI
knock-down between TC71 or EWS502 and A673 cells, the
gene expression pattern mediated by EWS/FLI was similar
regardless of the Ewing’s sarcoma cell line being assessed.
Genes that are involved in oncogenic transformation
mediated by EWS/FLI are likely to be similarly regulated in
different Ewing’s sarcoma cell lines. To identify these, we
compared genes that were up-regulated or down-regulated
(at P < 0.05) in TC71, EWS502, and A673 cells. There were 34
genes up-regulated, and 29 genes down-regulated by EWS/FLI
in all three Ewing’s sarcoma cell lines tested (Fig. 2B and C;
Tables 1 and 2).
The gene that was most correlated with EWS/FLI expression
across all of the data sets was NR0B1, which encodes the
NR0B1 protein (also known as DAX1, Fig. 2B and D; Table 1).
NR0B1 is an orphan nuclear receptor that is mutated in adrenal
hypoplasia congenita and hypogonadotropic hypogonadism
(12). Interestingly, NR0B1 has recently been suggested to be an
EWS/FLI target gene, however, the functional relevance of this
observation was not reported (16). Because NR0B1 expression
most correlated to EWS/FLI knock-down in our system, we
analyzed the function of NR0B1 in the development of Ewing’s
sarcoma.
We first validated the microarray data using Western blot
analysis. We assessed NR0B1 protein levels in TC71, EWS502,
and A673 cells. We found that NR0B1 protein levels were
significantly reduced when EWS/FLI was knocked-down in all
of these cells, supporting the hypothesis that NR0B1 is
regulated by EWS/FLI in Ewing’s sarcoma (Fig. 2E).
To determine the role of NR0B1 in Ewing’s sarcoma, we
developed a retroviral RNAi construct that targets the 3¶-
untranslated region of the NR0B1 transcript (designated
NR0B1-RNAi). This retrovirus was used to infect TC71,
EWS502, and A673 Ewing’s sarcoma cells. NR0B1-RNAi
efficiently knocked down NR0B1 protein levels, as compared
with the luc-RNAi control retrovirus (Fig. 3A).
We assessed the role of NR0B1 on the growth characteristics
of Ewing’s sarcoma cells in tissue culture using 3T5 growth
assays. Knock-down of NR0B1 resulted in a significant
inhibition of EWS502 and A673 growth, but not TC71 growth
(Fig. 3B). These growth patterns are reminiscent of the effects
we previously observed with EWS/FLI knock-down (Fig. 1B;
ref. 11). Interestingly, TC71 cells required EWS/FLI expres-
sion, but not NR0B1 expression, for normal tissue culture
growth. This suggests that a different EWS/FLI target gene (or
genes) is required for proliferation in tissue culture. In the case
of EWS502 and A673, NR0B1 is required for normal growth.
Expression of an NR0B1 cDNA that did not contain the
3¶-untranslated region (and was thus immune to the effect of
NR0B1-RNAi) partially rescued the growth deficit caused by
NR0B1 knock-down in EWS502 and A673 cells (Fig. 3B).
Thus, the observed effects were due to NR0B1 loss, and not an
off-target or other nonspecific RNAi effect (13). Supraphysio-
logic expression of NR0B1 seemed to be well-tolerated in all
three cell lines, as shown by the essentially unchanged growth
rate of cells expressing the control luc-RNAi and the NR0B1
cDNA, as compared with cells harboring the luc-RNAi and an
empty cDNA vector (Fig. 3B).
Soft agar assays were done to determine if the expression of
NR0B1 is also necessary for the transformed phenotype of
NR0B1 in EWS/FLI-Mediated Transformation
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853Ewing’s sarcoma cells. Reduction of NR0B1 levels resulted
in a significant reduction of oncogenic transformation in
TC71, EWS502, and A673 Ewing’s sarcoma cells (Fig. 3C).
Importantly, this was also true for TC71 cells, which main-
tained normal growth in tissue culture following NR0B1
knock-down (Fig. 3B), demonstrating that loss of transforma-
tion was not simply a consequence of diminished tissue culture
growth. Transformation was rescued following re-expression of
FIGURE 2. Microarray analysis of EWS/FLI target genes in Ewing’s sarcoma cells. A. Heat-map representation of the microarray data. Cells infected with
luc-RNAi( luc) are controls, whereas cells infected with either the EF-2-RNAi (labeled EF-2) or EF-4-RNAi( EF-4) have diminished EWS/FLI protein levels.
Each column indicates one cell sample, and each row indicates one gene. Red, genes that are relatively highly expressed; blue, genes that are expresseda t
relatively lower levels. The top 200 up-regulated and down-regulated genes are shown. B. Genes that were up-regulated by EWS/FLI in TC71 and EWS502
cells were compared with the genes that were up-regulated by EWS/FLI in A673 cells by GSEA (top left) and by m
2 analysis (top right). See text for details of
the statistical analysis. The 34 genes that were up-regulated by EWS/FLI in all three Ewing’s sarcoma cell lines are listed in Table 1.C. Genes that were down-
regulated by EWS/FLI in TC71 and EWS502 cells were compared with the genes that were down-regulated by EWS/FLI in A673 cells by GSEA (top left) and
by m
2 analysis (top right). The 29 genes that were down-regulated by EWS/FLI in all three Ewing’s sarcoma cell lines are listed in Table 2. D. NR0B1 was the
gene that was most reproducibly up-regulated by EWS/FLI in all of the cell types tested. The microarray data for NR0B1 in TC71 and EWS502 cells is shown
graphically. There are two probe sets for NR0B1 on the Affymetrix U133 Plus 2.0 array, and the data from each probe set is shown separately. Because two
distinct preparations of EWS502 cells were used for the microarray analysis, each one is shown separately to demonstrate the reproducibility of the data for
NR0B1. The data is normalized to 100% expression in luc-RNAi infected cells (red columns). Blue columns, NR0B1 expression in cells harboring the EF-2-
RNAior EF-4-RNAiconstructs. Columns, mean of dupli cate samples; bars, SD. E. Western blot analysis reveals that NR0B1 protein is down-regulated when
EWS/FLI is knocked-down with the EF-2-RNAi retroviral construct in TC71, EWS502, and A673 Ewing’s sarcoma cells. Tubulin is shown as a loading control.
Kinsey et al.
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854NR0B1 using the cDNA described above (Fig. 3C), demon-
strating that loss of transformation was due to loss of NR0B1
expression. NR0B1 expression was also required for xenograft
formation, because knock-down of the transcript diminished
tumor growth in vivo (Fig. 3D). Ongoing NR0B1 expression is
therefore required for oncogenic transformation in Ewing’s
sarcoma cells.
We next assessed the intrinsic oncogenic potential of
NR0B1. We introduced the NR0B1 cDNA into NIH3T3
immortalized murine fibroblasts. NIH3T3 cells are transformed
by a variety of oncogenes (including Ras and EWS/FLI) and are
a classic model system to assess oncogenic function (5, 17).
Although NIH3T3 cells infected with the NR0B1 cDNA-
containing retrovirus expressed robust levels of NR0B1 protein
(data not shown), these cells did not form colonies in soft agar
(Fig. 4A). Hence, NR0B1 does not cause oncogenic transfor-
mation in NIH3T3 cells.
To assess the oncogenic potential of NR0B1 in a system
related to Ewing’s sarcoma, we asked whether NR0B1 could
rescue the transformation defect in A673 cells caused by the
knock-down of EWS/FLI. A673 cells were first infected with
EF-2-RNAi retrovirus, and subsequently infected with the
NR0B1 cDNA retrovirus. These double-infected cells did not
form colonies in soft agar assays, although the EWS/FLI cDNA
did rescue transformation caused by knock-down of the
endogenous fusion protein (Fig. 4B). Taken together, we
conclude that NR0B1 does not function as an oncogene by
itself, but rather is a required downstream target of EWS/FLI in
Ewing’s sarcoma.
The insufficiency of NR0B1 alone to rescue oncogenic
transformation following knock-down of EWS/FLI suggested
that other EWS/FLI downstream targets participate in this
process. We recently identified NKX2.2 as another EWS/FLI
up-regulated gene that is required for oncogenic transformation
mediated by the fusion protein (11). We therefore asked
whether expression of both downstream targets, NR0B1 and
NKX2.2, could rescue the phenotype caused by EWS/FLI
knock-down. We introduced the cDNAs for both NR0B1 and
NKX2.2 into A673 Ewing’s sarcoma cells, and recovered a
population of cells that expressed both proteins using a
combination of neomycin and hygromycin selection. Control
cells were also prepared that contained the ‘‘empty-vector’’
controls for each marker. We then introduced either the EF-2-
RNAi, or control luc-RNAi, retroviral vectors. Following
additional selection in puromycin, these ‘‘triple-infectants’’
were assessed for oncogenic transformation. We found that
expression of both NR0B1 and NKX2.2 was insufficient to
rescue transformation (Fig. 4C). These data suggest that, in
addition to NR0B1 and NKX2.2, additional EWS/FLI dysre-
gulated targets also contribute to the transformed phenotype of
Ewing’s sarcoma cells.
If NR0B1 is a clinically relevant EWS/FLI target, it should
be expressed in primary patient-derived tumor samples in
addition to the cell lines described above. To test this
hypothesis, we did reverse transcriptase-PCR assays on total
RNA isolated from Ewing’s sarcoma tumor samples. We found
NR0B1 expression in four of four tumors analyzed, but not in
Table 1. Genes That Were Up-Regulated by EWS/FLI in All
Three Ewing’s Sarcoma Cell Lines
NR0B1 Nuclear receptor subfamily 0, group B, member 1
MKI67 Antigen identified by monoclonal antibody Ki-67
SLC29A1 Solute carrier family 29 (nucleoside transporters),
member 1
ARHGAP19 Rho GTPase activating protein 19
KIAA0101 KIAA0101
HRSP12 Heat-responsive protein 12
DLG7 Discs, large homologue 7 (Drosophila)
NMI N-myc (and STAT) interactor
FCGRT Fc fragment of IgG, receptor, transporter, A
DKC1 Dyskeratosis congenital 1, dyskerin
KIF14 Kinesin family member 14
TOP2A Topoisomerase (DNA) IIA, 170 kDa
STK6 Serine/threonine kinase 6
GSTM4 Glutathione S-transferase M4
DKFZP434L0117 Coiled-coil domain containing 21
STEAP Six transmembrane epithelial antigen of the prostate 1
SORD Similar to sorbitol dehydrogenase
(L-iditol 2-dehydrogenase)
FDX1 Ferredoxin 1
MAC30 Hypothetical protein MAC30
HMMR Hyaluronan-mediated motility receptor (RHAMM)
SKP2 S phase kinase-associated protein 2 (p45)
PRUNE Prune homologue (Drosophila)
DICER1 Dicer1, Dcr-1 homologue (Drosophila)
MPDU1 Mannose-P-dolichol utilization defect 1
SEPHS1 Selenophosphate synthetase 1
TMSNB Thymosin-like 8
CAV1 Caveolin 1, caveolae protein, 22 kDa
SSX2 Synovial sarcoma, X breakpoint 2
CIAPIN1 Cytokine induced apoptosis inhibitor 1
SRRM1 Serine/arginine repetitive matrix 1
GSTM1 Glutathione S-transferase M1
ZNF232 Zinc finger protein 232
E2IG5 Growth- and transformation-dependent protein
DNAJC12 DnaJ (Hsp40) homologue, subfamily C, member 12
Table 2. Genes That Were Down-Regulated by EWS/FLI In
All Three Ewing’s Sarcoma Cell Lines
DKK1 Dickkopf homologue 1 (Xenopus laevis)
NT5E 5¶-nucleotidase, ecto (CD73)
PLAUPlasminogen activator, urokinase
SAT Spermidine/spermine N1-acetyltransferase
KLF2 Kruppel-like factor 2 (lung)
CYR61 Cysteine-rich, angiogenic inducer, 61
NPC2 Niemann-Pick disease, type C2
SPARC Secreted protein, acidic, cysteine-rich (osteonectin)
LOX Lysyl oxidase
MGC3262 Yip1 domain family, member 2
IER3 Immediate early response 3
KIAA1539 KIAA1539
CLECSF2 C-type lectin domain family 2, member B
SPHK1 Sphingosine kinase 1
POSTN Periostin, osteoblast-specific factor
CST3 Cystatin C (amyloid angiopathy and cerebral hemorrhage)
CD59 CD59 antigen p18-20
TGFBR2 Transforming growth factor, h receptor II (70/80 kDa)
HLA-E MHC, class I, E
MGP Matrix Gla protein
CRABP1 Cellular retinoic acid binding protein 1
SGSH N-sulfoglucosamine sulfohydrolase (sulfamidase)
CREB3L1 CAMP-responsive element binding protein 3-like 1
PRSS23 Protease, serine 23
TETRAN Tetracycline transporter-like protein
CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4
COL1A1 Collagen, type I, a1
LTBP3 Latent transforming growth factor h binding protein 3
AMIGO2 Adhesion molecule with Ig-like domain 2
NR0B1 in EWS/FLI-Mediated Transformation
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855primary human fibroblasts (used as a negative control; Fig. 5A).
NR0B1 expression seems to be specific to Ewing’s sarcoma.
Western blot analysis of 37 different tumor cell lines revealed
that NR0B1 protein was only expressed in Ewing’s sarcoma
cells, but not in lines derived from non–Ewing’s sarcoma
tumor types (Fig. 5B).
The data presented here shows that NR0B1 is an EWS/FLI-
regulated gene that is necessary, but not sufficient, for
oncogenic transformation in Ewing’s sarcoma cells. Although
previous studies have documented NR0B1 expression in some
tumor types, such as adrenocortical, breast, and ovarian
carcinomas (18-20), a functional role for NR0B1 in cancer
development has not been shown. Our findings therefore
provide a novel role for this orphan nuclear receptor.
Surprisingly, we did not observe NR0B1 expression by Western
blot in cell lines derived from those tumor types previously
reported to express the protein (Fig. 5B; refs. 18-20). This
suggests that NR0B1 expression is not required for the growth
of these tumor types in tissue culture.
The mechanism by which NR0B1 participates in cancer
development is currently unknown. Prior work suggests that
NR0B1 functions as a transcriptional repressor or corepressor
FIGURE 3. NR0B1 is necessary for oncogenic transformation in Ewing’s sarcoma cells. A. Western blot analysis of TC71, EWS502, and A673 Ewing’s
sarcoma cells reveals that NR0B1 protein expression is efficiently reduced by the NR0B1-RNAi virus, as compared with the luc-RNAi control virus. Tubulin is
shown as a loading control. B. Growth (3T5) assays of TC71, EWS502, and A673 cells infected with combinations of the NR0B1 cDNA and NR0B1-RNAi
viruses. TC71 maintains normal growth characteristics, whereas EWS502 and A673 have reduced growth rates when NR0B1 expression is knocked down.
The growth phenotype is partially reversed by NR0B1 re-expression. C. Soft agar assays reveal a complete loss of oncogenic transformation (as measured
by colony formation) in all three Ewing’s sarcoma cell lines infected with the NR0B1-RNAi retrovirus. Transformation is rescued by re-expression of NR0B1
protein from the NR0B1 cDNA retrovirus. Columns, mean of duplicate samples; bars, SD. D. Murine xenograft experiments using A673 Ewing’s sarcoma
cells expressing a luc-neo fusion protein that were subsequently infected with either the ERG-RNAi or NR0B1-RNAi retroviruses show that NR0B1 is required
for tumor formation in immunodeficient mice. Left, bioluminescent imaging data; middle, tumor photon emission; right, tumor size, in which numbers indicate
separate tumor injection sites. P values from Student’s t tests are also shown.
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856(12, 21-25). We found that a large number of genes were down-
regulated by EWS/FLI. Future work will be required to
determine if NR0B1 is the central mediator of these down-
regulatory events.
The ligand for NR0B1, if one exists, is unknown. Therefore,
we do not know if NR0B1 functions as a repressor in the
presence of ligand. Other nuclear hormone receptors, such as
the estrogen receptor, androgen receptor, and retinoic acid
receptor, serve as important therapeutic targets in diseases such
as breast cancer, prostate cancer, and acute promyelocytic
leukemia, respectively (26-28). It is possible that a ligand
agonist or antagonist for NR0B1 may alter its function and
prevent its participation in Ewing’s sarcoma development.
Thus, the work presented in this report provides support for
evaluating NR0B1 as a potential therapeutic target. An NR0B1
agonist or antagonist may function as an antineoplastic agent
for Ewing’s sarcoma; such an agent would be most welcome for
this devastating pediatric cancer.
Materials and Methods
Constructs and Retroviruses
The EF-2-RNAi, EF-4-RNAi, and luc-RNAi retroviruses
were previously described (11). To generate the NR0B1-RNAi
retroviral vector, the following oligonucleotides were annealed
and cloned downstream of the U6 promoter in the pMKO.1P
vector (29):
NR0B1-RNAiF: 5¶-CCGGCCACACAAGTGCAGTAGTG-
TTCAAGAGACACTACTGCACTTGTGTGGTTTTTG-3¶,
NR0B1-RNAiR: 5¶-AATTCAAAAACCACACAAGT-
GCAGTAGTGTCTCTTGAACACTACTGCACTT-
GTGTGG-3¶.
The coding region of NR0B1 was amplified by reverse
transcriptase-PCR and cloned into the retroviral expression
vector pMSCV-Neo (Clontech, Mountain View, CA). The
coding region of EWS/FLI was cloned into the pMSCV-Hygro
vector (Clontech). Retroviral production and infection were
done as previously described (7).
Cell Culture
Ewing’s sarcoma cell lines were grown as described (7).
Following retroviral infection, polyclonal pools of cells were
selected and maintained in the appropriate selective medium
(2 Ag/mL for puromycin, 300 Ag/mL for G418, and 100 Ag/mL
FIGURE 4. NR0B1 is not sufficient for oncogenic transformation. A.
Soft agar assays show that whereas EWS/FLI expression causes
oncogenic transformation of NIH3T3 cells (as measured by colony
formation), NR0B1 expression does not. ‘‘Empty’’ MSCV-Hygro and
pMSCV-Neo are the control viruses for the adjacent samples. The
controls do not contain a cDNA. Columns, mean of duplicate samples;
bars, SD. B. Soft agar assays show that whereas EWS/FLI expression
rescues the loss of oncogenic transformation caused by the EF-2-RNAi
retroviral construct, NR0B1 expression does not. Columns, mean of
duplicate samples; bars, SD. C. Soft agar assays show that the
expression of both NR0B1 and NKX2.2 are insufficient to rescue
oncogenic transformation caused by the EF-2-RNAi retroviral construct.
Columns, mean of duplicate samples; bars, SD.
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857for hygromycin). The day when a control uninfected plate of
cells was completely dead was considered to be day 0 for
subsequent growth assays. Because the efficiency of infection is
relatively high (>50% of cells infected), adequate cells for later
assays could usually be obtained following drug selection, even
in cases in which the cells are growth-arrested.
Growth assays (3T5 assays) were done by plating 5  10
5
cells on a 10 cm (diameter) tissue culture dish in 10 mL of
selective growth medium. Cells were harvested and counted
3 days later, and 5  10
5 cells were replated on a new dish.
The process was repeated every 3 days for a total of 15 days.
Population doubling was calculated as the ln(cell count at day 3
post-plating/cell count plated) divided by ln(2). The cumulative
population doubling was calculated by adding the population
doubling at a given 3-day interval to the prior cumulative
population doubling up to that time point.
Soft agar assays were done as described (7). Quantitation of
agar colony formation was done using the Quantity One
software package (Bio-Rad, Hercules, CA). Details regarding
the growth of the non–Ewing’s sarcoma cell lines used is
included in Supplementary Methods online.
Xenograft Imaging
A673 cells were infected with pMMP-LucNeo and selected
with G418 (30). They were then infected with either NR0B1-
RNAi or ERG-RNAi retroviruses, and selected with puromy-
cin. Following selection, 1  10
6 cells were injected into the
flanks of nude mice. Mice were imaged weekly using a
Xenogen IVIS 100 imaging system, and used according to the
manufacturer’s directions. Animal experiments were done
following approval from the University of Utah Institutional
Animal Care and Use Committee.
Reverse Transcriptase-PCR
Total RNA samples derived from primary patient Ewing’s
sarcoma tumors were provided by Dr. R.L. Randall (Huntsman
Cancer Institute). NR0B1 and glyceraldehyde-3-phosphate
dehydrogenase fragments were amplified using a one-step
reverse transcriptase-PCR kit (Roche, Pleasanton, CA). Primer
sequences are available on request.
Microarray and Statistical Analysis
A complete description of the microarray analysis, GSEA,
and m
2 analysis is provided as Supplementary Methods online.
The complete microarray data set from the TC71 and EWS502
cell lines is provided as Supplementary Data 1 online. The
preprocessed data, rank-ordered data set, and up-regulated and
down-regulated gene sets are provided as Supplementary Data
2 online. The .cls file required to perform the described analysis
in either the GeneCluster 2.0 or GenePattern software packages
(Broad Institute, Cambridge, MA) is provided as Supplemen-
tary Data 3 online.
Western Blot
Protein lysates were prepared in protein lysis buffer [10
mmol/LTris (pH 7.6), 100 mmol/L NaCl, 1 mmol/L EDTA, 1%
Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS]
containing protease inhibitors. Total proteins (75-100 Ag) were
separated by SDS-PAGE, and transferred to nitrocellulose
membranes. Anti-NR0B1 (R&D Biosciences, Minneapolis,
MN), anti-FLI (Santa Cruz, Santa Cruz, CA), and anti-a-
tubulin (Santa Cruz) were used for immunodetection.
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